Skip to main content

Coronavirus Infections

Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trial.

Chalkias S. The Lancet Infectious Diseases 2025;:https://doi.org/10.1016/S1473-3099(25)00236-1.

Published on 12/8/2025
COVID-19 infection and severity among childhood cancer survivors in Denmark and Sweden: a register-based cohort study with matched population and sibling comparisons.

Louro J. The Lancet Regional Health – Europe 2025;:https://doi.org/10.1016/j.lanepe.2025.101363.

Published on 12/8/2025
Cancelled elective operations and 28-day breaches in the NHS in England: an interrupted time series analysis of the 2002 penalty policy, 2008 recession, and COVID-19 pandemic (1994–2023).

Quinn L. The Lancet Regional Health – Europe 2025;:https://doi.org/10.1016/j.lanepe.2025.101368.

Published on 12/8/2025
Impact of COVID-19 on disease-specific mortality, healthcare resource utilization, and disease burden across a population over 1 billion in 31 countries: an interrupted time-series analysis.

Choi K. eClinicalMedicine 2025;:https://doi.org/10.1016/j.eclinm.2025.103315.

Published on 12/8/2025
Sociodemographic patterns of COVID-19 mortality: the 2020 Japanese census-linked mortality database.

Tanaka H. The Lancet Regional Health – Western Pacific 2025;:https://doi.org/10.1016/j.lanwpc.2025.101609.

Published on 12/8/2025
Colorimetric RT-LAMP for SARS-CoV-2 detection from nasopharyngeal swabs or crude saliva: a multicountry diagnostic accuracy study in Africa.

Šušnjar U. The Lancet Global Health 2025;:https://doi.org/10.1016/S2214-109X(25)00150-0.

Published on 12/8/2025
Integrated virologic analysis of resistance to nirmatrelvir/ritonavir in individuals across four phase 2/3 clinical studies for the treatment of COVID-19.

Baniecki ML. eBioMedicine 2025;:https://doi.org/10.1016/j.ebiom.2025.105819.

Published on 12/8/2025
Long-term kidney outcomes after COVID-19: a matched cohort study using the OpenSAFELY platform.

Mahalingasivam V. The Lancet Regional Health – Europe 2025;:https://doi.org/10.1016/j.lanepe.2025.101338.

Published on 12/8/2025
Vaccine-induced T cell responses correlate with reduced risk of severe COVID-19 in a placebo-controlled efficacy trial.

Hertoghs N. eBioMedicine 2025;:https://doi.org/10.1016/j.ebiom.2025.105809.

Published on 12/8/2025
Derivation and validation of a point-based forecasting tool for SARS-CoV-2 critical care occupancy: a population-based modeling study.

Grima AA. The Lancet Regional Health – Americas 2025;:https://doi.org/10.1016/j.lana.2025.101143.

Published on 12/8/2025

...
13
14
15
16